Comparative Pharmacology
Head-to-head clinical analysis: MICRO K versus MICRO K 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICRO K versus MICRO K 10.
MICRO-K vs MICRO-K 10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium is the principal intracellular cation, essential for maintaining cellular tonicity, electrical neutrality, and enzymatic reactions. It modulates neuromuscular transmission, cardiac contractility, and acid-base balance.
Potassium is the major intracellular cation; it is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride is absorbed from the gastrointestinal tract and distributes throughout the body. The microencapsulated formulation allows for gradual release of potassium, minimizing gastrointestinal irritation.
Oral: 20-40 mEq (1-2 capsules) two to four times daily; maximum 100 mEq/day. Each capsule contains 8 mEq (600 mg) of potassium chloride in a wax matrix extended-release formulation.
10 mEq (2 capsules) orally once daily, or 20 mEq (2 capsules) twice daily, or as directed by physician. Maximum 100 mEq/day.
None Documented
None Documented
Not applicable; potassium is an electrolyte with no true elimination half-life; whole-body turnover half-life is approximately 12-24 hours, clinically relevant for dosing intervals.
Not applicable; potassium is not cleared by first-order kinetics. Whole-body potassium turnover half-life is approximately 30 days, but this is not clinically relevant for supplementation.
Renal: approximately 90% of absorbed potassium is excreted in urine; biliary/fecal: less than 10% eliminated via feces.
Primarily renal: 90% of absorbed potassium is excreted in urine as potassium ions; 10% eliminated in feces via biliary and intestinal secretion.
Category C
Category C
Electrolyte Supplement (Potassium)
Electrolyte Supplement (Potassium)